Envista Holdings Corporation (NVST)
NVST or ABT: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
Envista: Anticipating A FY25 Beat (Rating Upgrade)
Envista Holdings is upgraded from "Hold" to "Buy" ahead of its FY25 results, anticipating an earnings beat. Analyst forecasts appear overly conservative; NVST's cost optimization, share buybacks, and product traction suggest upside to consensus EPS. Recent investor events and sector surveys indicate strong momentum in implants, clear aligners, and diagnostic segments, with favorable market trends.
NVST vs. SYK: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Envista (NVST) and Stryker (SYK). But which of these two stocks is more attractive to value investors?
Envista Holdings Corporation (NVST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Envista Holdings Corporation (NVST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Here's Why You Should Add NVST Stock to Your Portfolio Right Now
Envista's global expansion, bolt-on acquisitions, and strong balance sheet support growth, even as currency swings pressure sales.
NVST vs. SYK: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Products sector might want to consider either Envista (NVST) or Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
Envista Holdings Corporation (NVST) Presents at Evercore 8th Annual Healthcare Conference Transcript
Envista Holdings Corporation (NVST) Presents at Evercore 8th Annual Healthcare Conference Transcript
Here's Why Envista (NVST) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Envista (NVST) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Envista Holdings Corporation (NVST) Q3 2025 Earnings Call Transcript
Envista Holdings Corporation ( NVST ) Q3 2025 Earnings Call October 30, 2025 5:00 PM EDT Company Participants Jim Gustafson - Vice President of Investor Relations Paul Keel - CEO & Director Eric Hammes - Senior VP & CFO Conference Call Participants Allen Lutz - BofA Securities, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Michael Cherny - Leerink Partners LLC, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Linda Bolduc - Morgan Stanley, Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Steven Valiquette - Mizuho Securities USA LLC, Research Division Michael Sarcone - Jefferies LLC, Research Division Russell Yuen - William Blair & Company L.L.C.
Envista (NVST) Earnings Expected to Grow: Should You Buy?
Envista (NVST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Envista (NVST) Beat Estimates Again in Its Next Earnings Report?
Envista (NVST) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
